Department of Medicine, New York University Langone Health, New York, New York.
Service de Médecine Intensive-Réanimation, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, DMU CORREVE, FHU SEPSIS, Groupe de Recherche CARMAS, Le Kremlin-Bicêtre, France.
Am J Respir Crit Care Med. 2023 Sep 15;208(6):685-694. doi: 10.1164/rccm.202212-2293OC.
Patients with obesity are at increased risk for developing acute respiratory distress syndrome (ARDS). Some centers consider obesity a relative contraindication to receiving extracorporeal membrane oxygenation (ECMO) support, despite growing implementation of ECMO for ARDS in the general population. To investigate the association between obesity and mortality in patients with ARDS receiving ECMO. In this large, international, multicenter, retrospective cohort study, we evaluated the association of obesity, defined as body mass index ⩾ 30 kg/m, with ICU mortality in patients receiving ECMO for ARDS by performing adjusted multivariable logistic regression and propensity score matching. Of 790 patients with ARDS receiving ECMO in our study, 320 had obesity. Of those, 24.1% died in the ICU, compared with 35.3% of patients without obesity ( < 0.001). In adjusted models, obesity was associated with lower ICU mortality (odds ratio, 0.63 [95% confidence interval, 0.43-0.93]; = 0.018). Examined as a continuous variable, higher body mass index was associated with decreased ICU mortality in multivariable regression (odds ratio, 0.97 [95% confidence interval, 0.95-1.00]; = 0.023). In propensity score matching of 199 patients with obesity to 199 patients without, patients with obesity had a lower probability of ICU death than those without (22.6% vs. 35.2%; = 0.007). Among patients receiving ECMO for ARDS, those with obesity had lower ICU mortality than patients without obesity in multivariable and propensity score matching analyses. Our findings support the notion that obesity should not be considered a general contraindication to ECMO.
肥胖患者发生急性呼吸窘迫综合征(ARDS)的风险增加。一些中心认为肥胖是接受体外膜氧合(ECMO)支持的相对禁忌证,尽管 ECMO 在普通人群中越来越多地用于 ARDS。 目的:探讨肥胖与接受 ECMO 的 ARDS 患者死亡率之间的关系。 在这项大型国际多中心回顾性队列研究中,我们通过进行调整后的多变量逻辑回归和倾向评分匹配,评估了肥胖(定义为 BMI≥30kg/m)与接受 ECMO 的 ARDS 患者 ICU 死亡率之间的关系。 在本研究中,790 名接受 ECMO 的 ARDS 患者中,有 320 名肥胖患者。其中,24.1%的患者在 ICU 死亡,而无肥胖的患者为 35.3%( < 0.001)。在调整后的模型中,肥胖与较低的 ICU 死亡率相关(比值比,0.63 [95%置信区间,0.43-0.93]; = 0.018)。作为连续变量进行检查时,多变量回归中 BMI 越高与 ICU 死亡率降低相关(比值比,0.97 [95%置信区间,0.95-1.00]; = 0.023)。在对 199 名肥胖患者和 199 名非肥胖患者进行倾向评分匹配后,肥胖患者的 ICU 死亡率低于非肥胖患者(22.6% vs. 35.2%; = 0.007)。 在接受 ECMO 治疗 ARDS 的患者中,肥胖患者在多变量和倾向评分匹配分析中 ICU 死亡率低于非肥胖患者。我们的研究结果支持这样一种观点,即肥胖不应被视为 ECMO 的一般禁忌证。